M
Mateusz Legut
Researcher at New York University
Publications - 35
Citations - 2097
Mateusz Legut is an academic researcher from New York University. The author has contributed to research in topics: CRISPR & T cell. The author has an hindex of 17, co-authored 27 publications receiving 1186 citations. Previous affiliations of Mateusz Legut include University of Wrocław & Cardiff University.
Papers
More filters
Journal ArticleDOI
Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells.
Zharko Daniloski,Tristan X. Jordan,Hans-Hermann Wessels,Daisy A. Hoagland,Silva Kasela,Mateusz Legut,Silas Maniatis,Eleni P. Mimitou,Lu Lu,Evan T. Geller,Oded Danziger,Brad R. Rosenberg,Hemali Phatnani,Peter Smibert,Tuuli Lappalainen,Benjamin R. tenOever,Neville E. Sanjana +16 more
TL;DR: Overall, this work provides a genome-scale, quantitative resource of the impact of the loss of each host gene on fitness/response to viral infection.
Journal ArticleDOI
Multiplexed detection of proteins, transcriptomes, clonotypes and CRISPR perturbations in single cells
Eleni P. Mimitou,Anthony Cheng,Antonino Montalbano,Stephanie Hao,Marlon Stoeckius,Mateusz Legut,Timothy Roush,Alberto Herrera,Efthymia Papalexi,Zhengqing Ouyang,Zhengqing Ouyang,Rahul Satija,Neville E. Sanjana,Sergei B. Koralov,Peter Smibert +14 more
TL;DR: Expanded CRISPR-compatible cellular indexing of transcriptomes and epitopes by sequencing (ECCITE-seq) is described for the high-throughput characterization of at least five modalities of information from each single cell.
Journal ArticleDOI
Massively parallel Cas13 screens reveal principles for guide RNA design
Hans-Hermann Wessels,Alejandro Méndez-Mancilla,Xinyi Guo,Mateusz Legut,Zharko Daniloski,Neville E. Sanjana +5 more
TL;DR: It is shown that Cas13 can be used in forward transcriptomic pooled screens and predicted optimized Cas13 gRNAs for all protein-coding transcripts in the human genome by computational modeling of large-scale screening data.
Journal ArticleDOI
Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
Paul Maciocia,Patrycja Wawrzyniecka,Brian Philip,Ida Ricciardelli,Ayse U. Akarca,Shimobi Onuoha,Mateusz Legut,David K. Cole,Andrew K. Sewell,Giuseppe Gritti,Joan Somja,Miguel A. Piris,Karl S. Peggs,David C. Linch,Teresa Marafioti,Martin Pule +15 more
TL;DR: A new targeting strategy based on the mutually exclusive expression of T cell receptor β-chain constant domains 1 and 2 (TRBC1 and TRBC2) is reported, which could eradicate a T cell malignancy while preserving sufficient normal T cells to maintain cellular immunity.
Journal ArticleDOI
Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1
Michael D. Crowther,Garry Dolton,Mateusz Legut,Marine E. Caillaud,Angharad Lloyd,Meriem Attaf,Sarah A. E. Galloway,Cristina Rius,Colin P. Farrell,Barbara Szomolay,Ann Ager,Alan L. Parker,Anna Fuller,Marco Donia,James McCluskey,Jamie Rossjohn,Inge Marie Svane,John D. Phillips,Andrew K. Sewell +18 more
TL;DR: It is demonstrated that the nonclassical MHC molecule MR1 is expressed on a wide variety of cancer types and can be targeted by conventional T cells, and offers opportunities for HLA-independent, pan-cancer,pan-population immunotherapies.